vs
高露洁棕榄（CL）与费森尤斯医疗（FMS）财务数据对比。点击上方公司名可切换其他公司
费森尤斯医疗的季度营收约是高露洁棕榄的1.0倍（$5.5B vs $5.3B），高露洁棕榄净利率更高（12.1% vs 7.9%，领先4.2%），高露洁棕榄同比增速更快（8.4% vs -0.3%）
高露洁棕榄是总部位于美国纽约市曼哈顿中城公园大道的跨国消费品企业，主营家居清洁、医疗护理、个人护理、宠物护理等品类产品的生产、分销及相关服务，旗下产品行销全球多地，在日用消费领域拥有广泛的市场认可度。
费森尤斯医疗是德国知名医疗保健企业，核心业务为肾脏透析服务，在全球运营4171家门诊透析中心，服务约34.54万名患者。公司主要为终末期肾病患者提供治疗服务，该类患者需终身每周接受3次透析治疗以维持生命。
CL vs FMS — 直观对比
营收规模更大
FMS
是对方的1.0倍
$5.3B
营收增速更快
CL
高出8.7%
-0.3%
净利率更高
CL
高出4.2%
7.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $5.5B |
| 净利润 | $646.0M | $434.2M |
| 毛利率 | 60.6% | 27.4% |
| 营业利润率 | 18.1% | 11.7% |
| 净利率 | 12.1% | 7.9% |
| 营收同比 | 8.4% | -0.3% |
| 净利润同比 | -6.4% | 240.4% |
| 每股收益（稀释后） | $0.80 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFMS
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.2B | $5.5B | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $5.1B | — | ||
| Q1 25 | $4.9B | — | ||
| Q4 24 | $4.9B | $5.5B | ||
| Q3 24 | $5.0B | — | ||
| Q2 24 | $5.1B | — |
净利润CLFMS
| Q1 26 | $646.0M | — | ||
| Q4 25 | $-36.0M | $434.2M | ||
| Q3 25 | $735.0M | — | ||
| Q2 25 | $743.0M | — | ||
| Q1 25 | $690.0M | — | ||
| Q4 24 | $738.0M | $127.6M | ||
| Q3 24 | $737.0M | — | ||
| Q2 24 | $731.0M | — |
毛利率CLFMS
| Q1 26 | 60.6% | — | ||
| Q4 25 | 60.2% | 27.4% | ||
| Q3 25 | 59.4% | — | ||
| Q2 25 | 60.1% | — | ||
| Q1 25 | 60.8% | — | ||
| Q4 24 | 60.3% | 25.0% | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 60.6% | — |
营业利润率CLFMS
| Q1 26 | 18.1% | — | ||
| Q4 25 | 1.7% | 11.7% | ||
| Q3 25 | 20.6% | — | ||
| Q2 25 | 21.1% | — | ||
| Q1 25 | 21.9% | — | ||
| Q4 24 | 21.5% | 5.1% | ||
| Q3 24 | 21.2% | — | ||
| Q2 24 | 21.6% | — |
净利率CLFMS
| Q1 26 | 12.1% | — | ||
| Q4 25 | -0.7% | 7.9% | ||
| Q3 25 | 14.3% | — | ||
| Q2 25 | 14.5% | — | ||
| Q1 25 | 14.1% | — | ||
| Q4 24 | 14.9% | 2.3% | ||
| Q3 24 | 14.6% | — | ||
| Q2 24 | 14.5% | — |
每股收益（稀释后）CLFMS
| Q1 26 | $0.80 | — | ||
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $0.91 | — | ||
| Q2 25 | $0.91 | — | ||
| Q1 25 | $0.85 | — | ||
| Q4 24 | $0.89 | — | ||
| Q3 24 | $0.90 | — | ||
| Q2 24 | $0.89 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $1.7B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $15.4B |
| 总资产 | $16.6B | $33.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLFMS
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.1B | — |
总债务CLFMS
| Q1 26 | — | — | ||
| Q4 25 | $7.8B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CLFMS
| Q1 26 | — | — | ||
| Q4 25 | $54.0M | $15.4B | ||
| Q3 25 | $856.0M | — | ||
| Q2 25 | $702.0M | — | ||
| Q1 25 | $363.0M | — | ||
| Q4 24 | $212.0M | $17.0B | ||
| Q3 24 | $435.0M | — | ||
| Q2 24 | $123.0M | — |
总资产CLFMS
| Q1 26 | $16.6B | — | ||
| Q4 25 | $16.3B | $33.5B | ||
| Q3 25 | $17.5B | — | ||
| Q2 25 | $17.5B | — | ||
| Q1 25 | $16.6B | — | ||
| Q4 24 | $16.0B | $36.3B | ||
| Q3 24 | $16.8B | — | ||
| Q2 24 | $16.5B | — |
负债/权益比CLFMS
| Q1 26 | — | — | ||
| Q4 25 | 145.17× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 33.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $2.9B |
| 自由现金流经营现金流 - 资本支出 | $609.0M | — |
| 自由现金流率自由现金流/营收 | 11.4% | — |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | — | 6.67× |
| 过去12个月自由现金流最近4个季度 | $3.8B | — |
8季度趋势，按日历期对齐
经营现金流CLFMS
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $2.9B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $884.0M | — | ||
| Q1 25 | $600.0M | — | ||
| Q4 24 | $1.3B | $2.6B | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $990.0M | — |
自由现金流CLFMS
| Q1 26 | $609.0M | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $776.0M | — | ||
| Q1 25 | $476.0M | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $873.0M | — |
自由现金流率CLFMS
| Q1 26 | 11.4% | — | ||
| Q4 25 | 24.4% | — | ||
| Q3 25 | 21.6% | — | ||
| Q2 25 | 15.2% | — | ||
| Q1 25 | 9.7% | — | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 20.5% | — | ||
| Q2 24 | 17.3% | — |
资本支出强度CLFMS
| Q1 26 | 2.6% | — | ||
| Q4 25 | 3.4% | — | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 2.3% | — |
现金转化率CLFMS
| Q1 26 | — | — | ||
| Q4 25 | — | 6.67× | ||
| Q3 25 | 1.72× | — | ||
| Q2 25 | 1.19× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 1.72× | 20.20× | ||
| Q3 24 | 1.58× | — | ||
| Q2 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CL
| Latin America | $1.3B | 25% |
| Pet Nutrition | $1.2B | 22% |
| Europe, Middle East & Africa (1) | $1.1B | 21% |
| North America (1) | $888.0M | 17% |
| Asia Pacific (1) | $804.0M | 15% |
FMS
暂无分部数据
